The exercise period for Alzinova's warrants of series TO2 2020/2022 begins today

In October 2020, Alzinova AB (publ) (“Alzinova” or the “Company”) carried out an issue of units with pre-emption rights for the shareholders (the “Rights Issue”), as well as an issue of units without pre-emption rights for the shareholders to the guarantors in the Rights Issue for their guaranteed commitments (the “Directed Issue”). The units issued in the Rights Issue and the Directed Issue consisted of shares and warrants of series TO2 2020/2022 (the “warrants”). The exercise period for the warrants begins today, January 24, 2022 and runs up to and including February 7, 2022. Two (2) warrants entitle the holder to subscribe for one (1) new share in Alzinova. The subscription price per share that is subscribed for through exercising the warrants has, in accordance with the terms and conditions for the warrants, been set to SEK 6.50. If all warrants are exercised, Alzinova will receive approximately SEK 26.5 million before issuing costs.

Comment from Alzinova’s CEO, Kristina Torfgård
”Now that we have taken our drug candidate, ALZ-101, into the clinical phase, we have reached an important intermediate goal in the work of developing a therapeutic vaccine directed against the neurotoxic oligomers for the treatment of Alzheimer's disease. Our goal of developing long-acting and effective treatments that enable patients to live an active and independent life, free from the effects of Alzheimer's disease, has now come a bit closer.
We look forward to your continued support and confidence in Alzinova's further development as weprepare and optimise the conditions for the start of a clinical phase 2 study." - Kristina Torfgård, CEO Alzinova

Summary of instructions and important dates
Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise well before February 7, 2022. Warrants that have not been exercised on or before February 7, 2022 expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including February 3, 2022.

‍Detailed information and instructions for subscription
Exercise of nominee-registered warrants
Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before February 7, 2022 as different nominees have different processing times.

Exercise of directly registered warrants
Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Hagberg Aneborn Fondkomission, no later than February 7, 2022.

The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.alzinova.com, www.hagberganeborn.se, www.redeye.se). Please note that payment for the new shares must be received by Hagberg Aneborn no later than February 7, 2022 in accordance with the instructions on the application form.

Trading in TO2 2020/2022
Holders who do not wish to exercise their warrants may sell them on Nasdaq First North Growth Market. The warrants are traded up to and including February 3, 2022 under the short name ALZ TO2 and with ISIN SE0014957270. Warrants that are not exercised on February 7, 2022 at the latest or sold on February 3, 2022 at the latest will expire without value.

Outcome and delivery of new shares
The outcome of the exercise of warrants will be published via a press release on or around February 10, 2022. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue have been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into ordinary shares in Alzinova.

Number of warrants and possible proceeds
The number of warrants amounts to 8,142,309. Upon full exercise of all warrants, Alzinova will receive approximately SEK 26.5 million before issuing costs. Upon full exercise of all warrants the number of shares in Alzinova will increase with 4,071,154 shares to 19,846,878 shares and the share capital will increase with SEK 1,070,713.502 to SEK 5,219,728.914. This entails a dilution of approximately 20.51 percent based on the number of shares in Alzinova after full exercise of all warrants.

Complete terms and conditions for the warrants
Complete terms and conditions for the warrants are available in the prospectus prepared by the Board of Directors of Alzinova in connection with the rights issue in 2020. The prospectus is available on the Company's, the issuing agent's and Redeye AB's respective websites. It is also available on Swedish Financial Supervisory Authority 's website www.fi.se.

Investor presentations
Alzinova will present at the Redeye Forum Special: Transactions on February 3, 2022. Information about the event is available on Redeye's website.

Advisers
Redeye AB acts as financial adviser, Fredersen Advokatbyrå AB acts as legal adviser and Hagberg Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue.

For more information, please contact:
Kristina Torfgård, VD Alzinova
Tel: +46 70 846 79 75
e-mail: kristina.torfgard@alzinova.com

About Alzinova
Alzinova AB (publ) is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 768-532 822. For more information about Alzinova, please visit: www.alzinova.com